Atezolizumab

About

Therapy type: Immunotherapy

Therapy strategy: PD-1/PD-L1 inhibition

Mappings

NCI Thesaurus: Atezolizumab (ncit:C106250)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 10% TIIC Non-Small Cell Lung Cancer Atezolizumab
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
EMA (1) FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab
EMA (1) FDA (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab
FDA (1) BRAF p.V600E Melanoma Atezolizumab, Cobimetinib, Vemurafenib
FDA (1) BRAF p.V600K Melanoma Atezolizumab, Cobimetinib, Vemurafenib
EMA (1) PD-L1 >= 5% Bladder Urothelial Carcinoma Atezolizumab
EMA (2) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
EMA (1) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1) Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) Wild type ALK Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
EMA (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel